Assessment of Patient Radiation Dose in Interventional Procedures at Shahid Madani Heart Center in Khorramabad, Iran

Introduction: Coronary angiography is the most common angiographic procedure for diagnosis and treatment of the heart diseases. Herein, we aimed to evaluate the entrance surface dose (ESD), dose area product (DAP), as well as cancer risk in interventional cardiology procedures. Materials and Methods: This study was conducted during July-December 2015 at Shahid Madani Heart Center in Khorramabad, Iran. A total of 225 adult patients including 122 females and 103 males regardless of the risk factors for coronary diseases were participated. Of them, 199 and 26 patients underwent diagnostic coronary angiography (CA) and percutaneous transluminal coronary angioplasty (PTCA), respectively. Each patient underwent CA or PTCA separately. All the procedures were carried out using Siemens angiography system with the pulsed fluoroscopy of 10-30 pulses/s and cine frame rate of 15 frames/s. DAP, ESD, fluoroscopy time (FT), as well as the number of sequences and frames per sequence were collected for each 199 CA and 26 PTCA procedures. Results: The median values of DAP were 19.77±14.88 and 57.11±33.36 Gy.cm2 in CA and PTCA, respectively. In addition, the median values of ESD were 323.12±245.39 and 1145.22±594.42 mGy in CA and PTCA, respectively. FTs were 114.59±74.33 s in CA and 424.15±292.93 s in PTCA. Conclusion: The average patient dose and cancer risk estimates in both CA and PTCA were consistent with the reference levels. However, in agreement with other interventional procedures, dose levels in the interventional cardiology are influenced by staff and clinical protocols, as well as the type of equipment

The global prevalence of gastric cancer in Helicobacter pylori-infected individuals: a systematic review and meta-analysis

Abstract Background Helicobacter pylori is a gastrointestinal pathogen that infects around half of the world's population. H. pylori infection is the most severe known risk factor for gastric cancer (GC), which is the second highest cause of cancer-related deaths globally. We conducted a systematic review and meta-analysis to assess the global prevalence of GC in H. pylori-infected individuals. Methods We performed a systematic search of the PubMed, Web of Science, and Embase databases for studies of the prevalence of GC in H. pylori-infected individuals published from 1 January 2011 to 20 April 2021. Metaprop package were used to calculate the pooled prevalence with 95% confidence interval. Random-effects model was applied to estimate the pooled prevalence. We also quantified it with the I2 index. Based on the Higgins classification approach, I2 values above 0.7 were determined as high heterogeneity. Results Among 17,438 reports screened, we assessed 1053 full-text articles for eligibility; 149 were included in the final analysis, comprising data from 32 countries. The highest and lowest prevalence was observed in America (pooled prevalence: 18.06%; 95% CI: 16.48 − 19.63; I2: 98.84%) and Africa (pooled prevalence: 9.52%; 95% CI: 5.92 − 13.12; I2: 88.39%). Among individual countries, Japan had the highest pooled prevalence of GC in H. pylori positive patients (Prevalence: 90.90%:95% CI: 83.61–95.14), whereas Sweden had the lowest prevalence (Prevalence: 0.07%; 95% CI: 0.06–0.09). The highest and lowest prevalence was observed in prospective case series (pooled prevalence: 23.13%; 95% CI: 20.41 − 25.85; I2: 97.70%) and retrospective cohort (pooled prevalence: 1.17%; 95% CI: 0.55 − 1.78; I 2: 0.10%). Conclusions H. pylori infection in GC patients varied between regions in this systematic review and meta-analysis. We observed that large amounts of GCs in developed countries are associated with H. pylori. Using these data, regional initiatives can be taken to prevent and eradicate H. pylori worldwide, thus reducing its complications